Condition: Frontotemporal Dementia · Frontotemporal Dementia, Behavioral Variant · Primary Progressive Aphasia · Sponsor: Simon Ducharme, MD
The primary goal of this study is to test the hypothesis that oral nabilone treatment will reduce agitation compared with placebo in patients with Frontotemporal Dementia (both behavioural variant frontotemporal dementia and primary progressive aphasia). The study population is defined as patients with probable Frontotemporal Dementia that meet the International Psychogeriatric Association criteria for agitation in cognitive disorders.
This description comes directly from the study's public registry record.
Contact details are listed per location below or on the registry record.
Always discuss trial participation with your own doctor first.
| University of British Columbia, St Paul's Hospital | Vancouver, British Columbia, Canada | — |
| Brain and Mind Institute, University of Western Ontario | London, Ontario, Canada | — |
| Sunnybrook Health Sciences Centre | Toronto, Ontario, Canada | — |
| Baycrest Hospital, University of Toronto | Toronto, Ontario, Canada | — |
| Western Hospital - University of Toronto | Toronto, Ontario, Canada | — |
| CHU de Québec, Université Laval | Laval, Quebec, Canada | — |
| The Douglas Research Centre | Montreal, Quebec, Canada | — |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05742698